# DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2])

> **NCT00273338** · PHASE3 · TERMINATED · sponsor: **Novacea** · enrollment: 1200 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** calcitriol
- **DRUG:** docetaxel

## Key facts

- **NCT ID:** NCT00273338
- **Lead sponsor:** Novacea
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-01
- **Primary completion:** —
- **Final completion:** 2007-11
- **Target enrollment:** 1200 (ESTIMATED)
- **Why stopped:** DSMB
- **Last updated:** 2007-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00273338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00273338, "DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2])". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT00273338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*